English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [1786]
News [2817]
Articles [109]
Editorials [3]
Conferences [102]
elearning [7]
PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning
Dr Shernan Holtan - University of Minnesota, Minneapolis, USA
PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning ( Dr Shernan Holtan - University of Minnesota, Minneapolis, USA )
15 Dec 2022
Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response...
Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA
Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease ( Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA )
15 Dec 2022
An analysis of the worldwide utilisation of haematopoietic stem cell...
Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA
An analysis of the worldwide utilisation of haematopoietic stem cell transplantation for acute myeloid leukaemia ( Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA )
14 Dec 2022
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable...
Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )
12 Dec 2022
Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable...
Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA
Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R follicular lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )
12 Dec 2022
Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows...
Dr Emma Searle - University of Manchester, Manchester, UK
Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma ( Dr Emma Searle - University of Manchester, Manchester, UK )
12 Dec 2022
Access to Oncology Medicines Coalition - The Medicines Patent Pool
Charles Gore - Medicines Patent Pool, Geneva, Switzerland
Access to Oncology Medicines Coalition - The Medicines Patent Pool ( Charles Gore - Medicines Patent Pool, Geneva, Switzerland )
1 Dec 2022
Isatuximab Subgroup Data Analyses Show Opportunity for Durable Responses in...
Prof Evangelos Terpos, Dr Marcelo Capra, Dr Fredrik Schjesvold, and Prof...
Isatuximab Subgroup Data Analyses Show Opportunity for Durable Responses in Elderly, Frail, and Renally Impaired Patients With RRMM ( Prof Evangelos Terpos, Dr Marcelo Capra, Dr Fredrik Schjesvold, and Prof Meletios Dimopoulos )
27 Oct 2022
Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival...
Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA
Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival benefit in R/R multiple myeloma ( Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA )
12 Oct 2022
Intraoperative Radiotherapy
Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal
Intraoperative Radiotherapy ( Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal )
25 Sep 2022
Cancer survivors' stories: An African perspective
Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation
Cancer survivors' stories: An African perspective ( Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation )
15 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
<1234567...149>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2023 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top